The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Open accessAbstract
Aim: Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery and for prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation. This open label, parallel group study investigated effects of extremes of body weight on apixaban pharmacokinetics, pharmacodynamics, safety and tolerability. Method: Fifty‐four healthy subjects were enrolled [18 each into low (≤50 kg), reference (65–85 kg) and high (≥120 kg) body weight groups]. Following administration of a single oral dose of 10 mg apixaban, plasma and urine samples were collected for determination of apixaban pharmacokinetics and anti‐factor X a activity. Adverse events, vital signs and laboratory assessments were monitored. Results: Compared with the reference body weight group, low body weight had approximately 27% [90% confidence interval (CI): 8–51%] and 20% (90% CI: 11–42%) higher apixaban maximum observed plasma concentration (Cmax) and area under the concentration–time curve extrapolated to infinity (AUC(0,∞)), respectively, and high body weight had approximately 31% (90% CI: 18–41%) and 23% (90% CI: 9–35%) lower apixaban Cmax and AUC(0,∞), respectively. Apixaban renal clearance was similar across the weight groups. Plasma anti‐factor X a activity showed a direct, linear relationship with apixaban plasma concentration, regardless of body weight group. Apixaban was well tolerated in this study. Conclusion: The modest change in apixaban exposure is unlikely to require dose adjustment for apixaban based on body weight alone. However, caution is warranted in the presence of additional factors (such as severe renal impairment) that could increase apixaban exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics
Anderson, B. J., & Holford, N. H. G. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094708 · Cited by 1,125
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Portman, R. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810773 · Cited by 695
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
Self-citationAtrial fibrillation and obesity—results of a meta-analysis
Wanahita, N., Messerli, F. H., Bangalore, S., Gami, A. S., Somers, V. K., & Steinberg, J. S. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.10.004 · Cited by 474
Pinto, D. J. P., Orwat, M. J., Koch, S., Rossi, K. A., Alexander, R. S., Smallwood, A., Wong, P. C., Rendina, A. R., Luettgen, J. M., Knabb, R. M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070245n · Cited by 402
Frost, C., Wang, J., Nepal, S., Schuster, A., Barrett, Y. C., Mosqueda‐Garcia, R., Reeves, R. A., & LaCreta, F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04369.x · Cited by 370
Self-citationOverweight, Obesity, and the Risk of Recurrent Venous Thromboembolism
Eichinger, S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1678 · Cited by 361
Wang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Self-citationKubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
WONG, P. C., CRAIN, E. J., XIN, B., WEXLER, R. R., LAM, P. Y. S., PINTO, D. J., LUETTGEN, J. M., & KNABB, R. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02939.x · Cited by 300
Nutescu, E. A., Spinier, S. A., Wittkowsky, A., & Dager, W. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l194 · Cited by 289
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Self-citationKubitza, D., Becka, M., Roth, A., & Mueck, W. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802361499 · Cited by 268
Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. A., Maxwell, B. D., Chen, S.-Y., He, K., Goosen, T. C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029694 · Cited by 253
Self-citationBULLER, H., DEITCHMAN, D., PRINS, M., & SEGERS, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03054.x · Cited by 252
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers
Sanderink, G., Le Liboux, A., Jariwala, N., Harding, N., Ozoux, M., Shukla, U., Montay, G., Boutouyrie, B., & Miro, A. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127114 · Cited by 186
Relationships between body mass indices and surgical replacements of knee and hip joints
Wendelboe, A. M., Hegmann, K. T., Biggs, J. J., Cox, C. M., Portmann, A. J., Gildea, J. H., Gren, L. H., & Lyon, J. L. (2003) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(03)00218-6 · Cited by 157
Patient-Specific Factors Predictive of Warfarin Dosage Requirements
Absher, R. K., Moore, M. E., & Parker, M. H. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1c025 · Cited by 105
Anticoagulating obese patients in the modern era
Patel, J. P., Roberts, L. N., & Arya, R. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08826.x · Cited by 104
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0007 · Cited by 78
Pineo, G. F., Gallus, A. S., Raskob, G. E., CHEN, D., Ramirez, L. M., Ramacciotti, E., Lassen, M. R., & Wang, L. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12109 · Cited by 38
Frost, C. E., Shenker, A., Jhee, S. S., Yu, Z., Wang, J. J. J., Bragat, A., Pursley, J. M., & LaCreta, F. P. (2018) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s169505 · Cited by 22
Self-citation
Cited by
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Chen, A., Stecker, E., & A. Warden, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017559 · Cited by 666
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Metadata
- Authors
- Upreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-11-20
- Volume
- 76
- Issue
- 6
- Pages
- 908-916
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2130340163
- Cited by
- 269
- References
- 31
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.